On Invalid Date, Ispecimen (NASDAQ: ISPC) reported Q2 2023 earnings per share (EPS) of -$0.39, up 30% year over year. Total Ispecimen earnings for the quarter were -$3.48 million. In the same quarter last year, Ispecimen's earnings per share (EPS) was -$0.30.
On Invalid Date, Ispecimen (NASDAQ: ISPC) reported Q2 2023 revenue of $1.63 million up 30.51% year over year. In the same quarter last year, Ispecimen's revenue was $2.34 million.
What was ISPC's revenue growth in the past year?
As of Q3 2023, Ispecimen's revenue has grown -0.05% year over year. This is 1.96 percentage points lower than the US Diagnostics & Research industry revenue growth rate of 1.91%. Ispecimen's revenue in the past year totalled $10.12 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.